AUTHOR=McKenzie Nathalie Dauphin , Kobetz Erin N. , Ganjei-Azar Parvin , Rosa-Cunha Isabella , Potter JoNell E. , Morishita Atsushi , Lucci Joseph A. , Guettouche Toumy , Hnatyszyn James H. , Koru-Sengul Tulay
TITLE=HPV in HIV-Infected Women: Implications for Primary Prevention
JOURNAL=Frontiers in Oncology
VOLUME=4
YEAR=2014
URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2014.00179
DOI=10.3389/fonc.2014.00179
ISSN=2234-943X
ABSTRACT=
Background: There is growing evidence that human immunodeficiency virus (HIV)-infected women might have a different human papillomavirus (HPV) type distribution in cervical dysplasia specimens as compared to the general population. This has implications for primary prevention.
Objective: We aimed to obtain preliminary data on the HPV genotypes prevalent in histological samples of HIV-infected women with cervical intraepithelial neoplasia (CIN) 3/CIS of the cervix in Miami, FL, USA.
Methods: Retrospective data were collected on HIV-infected women referred to the University of Miami-Jackson Memorial Hospital colposcopy clinic between years 2000 and 2008. The histology slides of CIN 3/CIS biopsies underwent pathological review and sections were cut from these archived specimens for HPV DNA extraction. HPV genotyping was then performed using the GeneSquareâ„¢ HPV genotyping assay. We report on our first set of 23 samples.
Results: Eight high-risk HPV types were detected. Types in decreasing order of frequency were 16, 35, 45, 52, 59, 31, 58, and 56. Most cases had multiple infections. HPV type 16 was the most common (45%) followed by HPV-35 and -45 with equal frequency (40%). No samples contained HPV-18.
Conclusion: Our preliminary results suggest that cervical dysplasia specimens of HIV-infected women more likely (55%) contain non-16 and -18 high-risk HPV types. We show that this held true for histologically confirmed severe dysplasia and carcinoma-in situ. Epidemiological studies guide vaccine development, therefore HPV type prevalence in CIS and invasive cervical cancer among HIV-infected women should be more rigorously explored to ensure that this highly vulnerable population receives appropriate primary prevention.